Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863053 | 0.91 | CYP4F2 (0.55) | CA2CYP4F2CYP4A11TP53POLB | |
| SCHEMBL5863075 | 0.88 | BCL2 (0.49) | CA2CYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL5863054 | 0.87 | CA2 (0.49) | CA2HPGDNPC1RAB9A | |
| SCHEMBL5863113 | 0.84 | MEN1 (0.51) | CA2POLBNPC1RAB9A | |
| SCHEMBL8873010 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11TP53POLBHPGD | |
| SCHEMBL4193217 | 0.81 | TP53 (0.61) | CA2CYP4F2CYP4A11TP53POLB | |
| SCHEMBL5863108 | 0.81 | CYP4F2 (0.46) | CA2CYP4F2CYP4A11TP53POLB | |
| SCHEMBL27542212 | 0.80 | NPC1 (0.52) | CYP4F2CYP4A11TP53POLBHPGD | |
| SCHEMBL29617015 | 0.80 | TP53 (0.62) | CA2CYP4F2CYP4A11TP53POLB | |
| SCHEMBL8873024 | 0.79 | NPC1 (0.55) | CYP4F2CYP4A11TP53POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CA2 2525/4885CYP4F2 3158/4885CYP4A11 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.